Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2010-12-7
pubmed:abstractText
Due to immunological monitoring, most of aggressive tumor cells are selected capable of producing soluble factors of immunosuppression in their microenvironment. A ligand for NK- and T-cells receptor (MICA/B) activation is one of them. We investigated MICA concentrations in serum of 10 healthy volunteers and 114 patients with solid tumors (breast cancer - 24, gastrointestinal tumors - 27, renal cell carcinoma - 15, lung cancer - 9, ovarian carcinoma - 13, cutaneous melanoma - 18, primary multiple tumors - 2, prostate cancer - 6). The lowest level of MICA was reported in ovarian carcinoma (91.19 +/- 29.42 pg/ml), the highest - in rectal cancer (311.13 +/- 50.11 pg/ml) while mean concentration in healthy volunteers was (19.38 +/- 5.91 pg/ml). Cells of melanoma, renal cell carcinoma and prostate cancer became capable of producing MICA during cultivation and antitumor vaccine preparation. It is suggested that culture supernatants be tested for MICA contents as well as patients screened for vaccination. Selection of patients should be carried out on the basis of MICA molecules detection in blood flow.
pubmed:language
rus
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0507-3758
pubmed:author
pubmed:issnType
Print
pubmed:volume
56
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
576-82
pubmed:meshHeading
pubmed-meshheading:21137238-Adult, pubmed-meshheading:21137238-Aged, pubmed-meshheading:21137238-Cancer Vaccines, pubmed-meshheading:21137238-Carcinoma, Renal Cell, pubmed-meshheading:21137238-Drug Design, pubmed-meshheading:21137238-Female, pubmed-meshheading:21137238-Histocompatibility Antigens Class I, pubmed-meshheading:21137238-Humans, pubmed-meshheading:21137238-Immunochemistry, pubmed-meshheading:21137238-Kidney Neoplasms, pubmed-meshheading:21137238-Male, pubmed-meshheading:21137238-Melanoma, pubmed-meshheading:21137238-Middle Aged, pubmed-meshheading:21137238-Neoplasms, pubmed-meshheading:21137238-Ovarian Neoplasms, pubmed-meshheading:21137238-Patient Selection, pubmed-meshheading:21137238-Prostatic Neoplasms, pubmed-meshheading:21137238-Receptors, Antigen, T-Cell, pubmed-meshheading:21137238-Receptors, Natural Killer Cell, pubmed-meshheading:21137238-Rectal Neoplasms
pubmed:year
2010
pubmed:articleTitle
[Immunochemical assay of MIC A production by tumor cells in vitro and in vivo as a component of antitumor vaccine development].
pubmed:publicationType
Journal Article, Comparative Study, English Abstract